395 related articles for article (PubMed ID: 37217353)
21. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010).
Hashimoto T; Tsukamoto S; Murofushi K; Ito Y; Hirano H; Tsukada Y; Sasaki K; Mizusawa J; Fukuda H; Takashima A; Kanemitsu Y
BJS Open; 2023 Nov; 7(6):. PubMed ID: 37931233
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
23. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
24. Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer Center.
Zhai ML; Zhang FY; Yang JR; Zhang S; Zhao L; Lin ZY; Wang J; Yu DD; Zhang T
Radiat Oncol; 2022 Jun; 17(1):109. PubMed ID: 35718789
[TBL] [Abstract][Full Text] [Related]
25. Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
Kang MK; Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Cho SH; Seo AN; Kim DW; Kim J; Baek SJ; Kim JH; Kim JY; Ha GW; Park EJ; Park IJ; Kim CH; Kang H; Choi GS
BMC Cancer; 2023 Nov; 23(1):1059. PubMed ID: 37923987
[TBL] [Abstract][Full Text] [Related]
26. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
27. ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
Alvarez J; Shi Q; Dasari A; Garcia-Aguilar J; Sanoff H; George TJ; Hong TS; Yothers G; Philip PA; Nelson GD; Al Baghdadi T; Alese O; Zambare W; Omer DM; Verheij FS; Buckley J; Williams H; George M; Garcia R; O'Reilly EM; Meyerhardt JA; Shergill A; Horvat N; Romesser PB; Hall WA; Smith JJ
medRxiv; 2024 Apr; ():. PubMed ID: 38712176
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation.
Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
Front Immunol; 2022; 13():1067036. PubMed ID: 36569918
[TBL] [Abstract][Full Text] [Related]
29. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial.
Chakrabarti D; Rajan S; Akhtar N; Qayoom S; Gupta S; Verma M; Srivastava K; Kumar V; Bhatt MLB; Gupta R
Br J Surg; 2021 May; 108(5):511-520. PubMed ID: 33724296
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F
Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346
[TBL] [Abstract][Full Text] [Related]
31. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial.
Wang X; Yu Y; Meng W; Jiang D; Deng X; Wu B; Zhuang H; Wang C; Shen Y; Yang L; Zhu H; Cheng K; Zhao Y; Li Z; Qiu M; Gou H; Bi F; Xu F; Zhong R; Bai S; Wang Z; Zhou Z
Radiother Oncol; 2018 Nov; 129(2):300-305. PubMed ID: 30381141
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.
Chen G; Jin Y; Guan WL; Zhang RX; Xiao WW; Cai PQ; Liu M; Lin JZ; Wang FL; Li C; Quan TT; Xi SY; Zhang HZ; Pan ZZ; Wang F; Xu RH
Lancet Gastroenterol Hepatol; 2023 May; 8(5):422-431. PubMed ID: 36870360
[TBL] [Abstract][Full Text] [Related]
33. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
[TBL] [Abstract][Full Text] [Related]
34. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
Jia AY; Narang A; Safar B; Zaheer A; Murphy A; Azad NS; Gearhart S; Fang S; Efron J; Warczynski T; Hacker-Prietz A; Meyer J
Radiat Oncol; 2019 Aug; 14(1):147. PubMed ID: 31426827
[TBL] [Abstract][Full Text] [Related]
35. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
[TBL] [Abstract][Full Text] [Related]
37. Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.
Li Y; Pan C; Gao Y; Zhang L; Ji D; Cui X; Zhang X; Cai Y; Zhang Y; Yao Y; Wang L; Leng J; Zhan T; Wu D; Gao Z; Sun YS; Li Z; Luo H; Wu A
JAMA Surg; 2024 May; 159(5):529-537. PubMed ID: 38381429
[TBL] [Abstract][Full Text] [Related]
38. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
[TBL] [Abstract][Full Text] [Related]
39. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.
Lin Z; Cai M; Zhang P; Li G; Liu T; Li X; Cai K; Nie X; Wang J; Liu J; Liu H; Zhang W; Gao J; Wu C; Wang L; Fan J; Zhang L; Wang Z; Hou Z; Ma C; Yang K; Wu G; Tao K; Zhang T
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725214
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
